# Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

> **NCT02413736** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Heikki Joensuu** · enrollment: 255 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT02413736
- **Lead sponsor:** Heikki Joensuu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-05
- **Primary completion:** 2026-06
- **Final completion:** 2033-06
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413736, "Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02413736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*